Pamidronic acid
Generic name
Pamidronic acid
Brand name
ATC Code
M05BA03
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Chronic or non-severe symptomatic hypercalcaemia |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Because pamidronic acid binds to bone tissue, it can disrupt bone scintigraphy.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Bisphosphonates | ||
|---|---|---|
| M05BA04 | ||
| M05BA07 | ||
| Other drugs affecting bone structure and mineralization | ||
|---|---|---|
| M05BX05 | ||
| M05BX04 | ||
References
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
- Noordam C et al, Werkboek Kinderendocrinologie, digitale publicatie op www.nvk.nl (alleen leden), 2010
- medac, SmPC Pamifos 3mg/ml Konzentrat zur Herstellung einer Infusionslösung (59200.00.00), 11/2015
- Hexal, SmPC Pamidron 15mg/ml Konzentrat zur Herstellung einer Infusionslösung (58750.00.00), 11/2016
- ribosepharm, SmPC Ribodronat 3mg/ml Konzentrat zur Herstellung einer Infusionslösung (61521.00.00), 02/2017
Changes
Therapeutic Drug Monitoring
Overdose
